Pharmaceutical giant Zydus Cadila has revealed to the Centre that it will file for emergency use authorization (EUA) for its vaccine candidate ZyCoV-D vaccine in the span of the next seven-eight days.
The vaccine will be the second indigenous vaccine to apply for authorization and be the first DNA vaccine in the world against the novel Coronavirus.
According to a government source, “Zydus Cadila has told the government that it could apply for emergency use authorization for ZyCoV-D vaccine in the next seven-eight days.”
ZyCoV-D is a type of Covid-19 DNA vaccine, which carries the genetic code for that specific part of the virus which induces the immune system of the body.
Dr. VK Paul, NITI Aayog member (health) told ANI that Zydus Cadila has registered over 28,000 volunteers for the phase III study.
Paul said, “We are hoping that they will apply in near future. Most of their study is complete. They have enrolled more than 28,000 volunteers in their phase-3 study. We expect they will submit the results very soon. We are hopeful of this vaccine because it would be the world’s first DNA vaccine. We are very proud of their vaccine.”
The vaccine is developed with assistance from the Central government’s National Biopharma Mission under the Biotechnology Industry Research Assistance Council, Department of Biotechnology.
Presently, India has granted approval for three Covid-19 vaccines – Bharat Biotech’s Covaxin, Serum Institute of India’s Covishield and Russian vaccine Sputnik V.
- Bengaluru metro to function on weekdays, closed on weekends from July 1
- India provides reciprocal exemption of EU Digital COVID Certificate to include Covishield, Covaxin
- PM Modi will address the Digital India beneficiaries at 11 am tomorrow
- Pvt hospitals will obtain Covid vaccine doses via CoWIN starting from July 1
- DGCA further extends the ban on international flights till July 31 due to Covid-19